---
title: "NRSN.US (NRSN.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/NRSN.US/news.md"
symbol: "NRSN.US"
name: "NRSN.US"
parent: "https://longbridge.com/zh-CN/quote/NRSN.US.md"
datetime: "2026-03-10T18:07:46.083Z"
locales:
  - [en](https://longbridge.com/en/quote/NRSN.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NRSN.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NRSN.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/NRSN.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/NRSN.US/news.md)


# NRSN.US (NRSN.US) — 相关新闻

### [This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday](https://longbridge.com/zh-CN/news/278561523.md)
*2026-03-10T12:50:11.000Z*
> Top Wall Street analysts have initiated coverage on several companies with varying ratings. Mizuho's Salim Syed rated Ma

### [Tryptamine-Linked Entropy Neurodynamics Director Increases Equity Stake via Off-Market Transfer](https://longbridge.com/zh-CN/news/278477255.md)
*2026-03-10T02:17:43.000Z*
> Tryptamine-Linked Entropy Neurodynamics Director Increases Equity Stake via Off-Market Transfer

### [PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference | NRSN Stock News](https://longbridge.com/zh-CN/news/278414606.md)
*2026-03-09T07:07:00.000Z*
> NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced that long-term survival data from its Phase 2b PARADIGM trial of P

### [17:31 ETDrug-Resistant Epilepsy Market to Accelerate With Significant CAGR by 2036 as Demand for Advanced Therapies Increases | DelveInsight](https://longbridge.com/zh-CN/news/276796435.md)
*2026-02-24T22:32:17.000Z*
> DelveInsight forecasts significant growth in the drug-resistant epilepsy market from 2025 to 2034, driven by rising prev

### [Pre-market hot trades in US stocks: NeuroSense Therapeutics - Unit up 7.84% in pre-market; Super Micro Computer up 4.64% in pre-market](https://longbridge.com/zh-CN/news/276339926.md)
*2026-02-19T13:42:43.000Z*
> NeuroSense Therapeutics - Unit pre-market up 7.84%; Super Micro Computer pre-market up 4.64%; Rubico pre-market up 73.21

### [](https://longbridge.com/zh-CN/news/276256032.md)
*2026-02-18T17:15:08.000Z*
> NeuroSense Therapeutics shares are trading lower. The company announced the availability of additional long-term surviva

### [05:30 ETLenire Shows Consistent Positive Results for U.S. Tinnitus Patients in 2nd Peer-Reviewed Real-World Study](https://longbridge.com/zh-CN/news/276112637.md)
*2026-02-17T10:30:40.000Z*
> Lenire, the only FDA-approved tinnitus treatment device, has shown consistent positive results in a second peer-reviewed